- Home
- IBRX vs MEOH Comparison
IBRX vs MEOH Comparison
Compare IBRX & MEOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- MEOH
- Stock Information
- Founded
- IBRX 2014
- MEOH 1968
- Country
- IBRX United States
- MEOH Canada
- Employees
- IBRX N/A
- MEOH N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- MEOH Major Chemicals
- Sector
- IBRX Health Care
- MEOH Industrials
- Exchange
- IBRX Nasdaq
- MEOH Nasdaq
- Market Cap
- IBRX 2.3B
- MEOH 2.2B
- IPO Year
- IBRX N/A
- MEOH N/A
- Fundamental
- Price
- IBRX $2.81
- MEOH $33.33
- Analyst Decision
- IBRX Strong Buy
- MEOH Buy
- Analyst Count
- IBRX 5
- MEOH 9
- Target Price
- IBRX $11.40
- MEOH $47.00
- AVG Volume (30 Days)
- IBRX 7.3M
- MEOH 825.5K
- Earning Date
- IBRX 08-11-2025
- MEOH 07-30-2025
- Dividend Yield
- IBRX N/A
- MEOH 2.20%
- EPS Growth
- IBRX N/A
- MEOH 24.27
- EPS
- IBRX N/A
- MEOH 3.06
- Revenue
- IBRX $31,222,000.00
- MEOH $3,700,592,000.00
- Revenue This Year
- IBRX $567.98
- MEOH $10.01
- Revenue Next Year
- IBRX $160.56
- MEOH $14.10
- P/E Ratio
- IBRX N/A
- MEOH $11.66
- Revenue Growth
- IBRX 10238.41
- MEOH 2.77
- 52 Week Low
- IBRX $1.83
- MEOH $25.46
- 52 Week High
- IBRX $7.48
- MEOH $54.49
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- MEOH 45.31
- Support Level
- IBRX $2.68
- MEOH $33.71
- Resistance Level
- IBRX $3.00
- MEOH $35.45
- Average True Range (ATR)
- IBRX 0.16
- MEOH 1.18
- MACD
- IBRX -0.00
- MEOH -0.17
- Stochastic Oscillator
- IBRX 62.00
- MEOH 13.36
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About MEOH Methanex Corporation
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through a global supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.